AbbVie

Two businessmen pushing giant puzzle pieces together as the sun sets behind them
Biotech

AbbVie inks $10.9B Apogee buyout to bag eczema prospect

The deal will give AbbVie control of a late-phase eczema drug candidate that could pose a threat to Eli Lilly, Regeneron and Sanofi.
Nick Paul Taylor Jun 22, 2026 7:59am
White arrow on a road pointing to the rising sun

Avalo’s phase 2 win fuels AbbVie chase despite placebo headwind

May 6, 2026 6:00am
Kestrel perched on a branch

AbbVie dips into boiling RAS waters with $1.45B biobucks deal

Apr 28, 2026 10:01am
Graphic of a puzzle depicting both the US and Chinese flags with missing pieces bridging the two together

AbbVie inks $745M deal with China’s Haisco for two pain assets

Apr 13, 2026 9:48am
MA combine

Alzheimer's-focused Korsana uses Cyclerion merger to go public

Apr 1, 2026 9:54am
Wooden blocks with arrow and error icon Delays and disruptions stop the process critical error concept

FDA rejects Aldeyra eye disease candidate for 3rd time

Mar 17, 2026 11:12am